AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11934908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 10224805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 10 mg dydrogesterone twice daily
Number of subjects: 56
Study 10224805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular HCG administration 1500 IU every 4 days and 10 mg dydrogesterone twice daily
Number of subjects: 56
Study 10224805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7972382 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of broad-spectrum sunscreens with low SPF
Number of subjects: 0
Study 7972382 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of broad-spectrum sunscreens with increasing SPF
Number of subjects: 0
Study 7972382 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum, highly protective sunscreens
Number of subjects: 0
Study 7972382 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical estimation of cis-UCA distribution
Number of subjects: 0
Study 7972382 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of cis-UCA from the stratum corneum
Number of subjects: 0
Study 2524407 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCEED(TC7)
Number of subjects: 74
Study 2524407 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated sidewall)
Number of subjects: 74
Study 29549104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg of 0.1% E2 gel per day
Number of subjects: 37
Study 29549104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg of 0.1% E2 gel per day
Number of subjects: 37
Study 29549104 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 37
Study 29549104 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 treatment
Number of subjects: 37
Study 28781213 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Replacement Therapy (TRT)
Number of subjects: 999
Study 28781213 — intervention group
Group type: COMPARATOR
Intervention: Not on TRT (untreated patients)
Number of subjects: 999
Study 25407693 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention (two 3-hour schooling modules of group education)
Number of subjects: 193
Study 25407693 — intervention group
Group type: COMPARATOR
Intervention: Standard auto-injector training (control group)
Number of subjects: 193
Study 23186730 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance classes (2 classes per week) and 30 minutes of daily self-imposed physical activity for 12 weeks
Number of subjects: 62
Study 23186730 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic dance intervention)
Number of subjects: 62
Study 21195382 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline plus metronidazole
Number of subjects: 56
Study 21195382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21195382 — intervention group
Group type: COMPARATOR
Intervention: No treatment (observational cohort with additional 75 cases)
Number of subjects: 56
Study 18499950 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education and physical therapy (1 appointment with physiatrist, 2 practical classes with physiotherapist)
Number of subjects: 45
Study 18499950 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education and physical therapy
Number of subjects: 45
Study 18499950 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative education and physical therapy)
Number of subjects: 45
Study 16567641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone (25 mg) administered orally 1 h before a socio-evaluative stressor
Number of subjects: 60
Study 16567641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (10 mg), repeated oral administration 1 h before exposure to a spider photograph
Number of subjects: 60
Study 16567641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14672103 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a lucky garment, taking a test-preparation course, staying up late
Number of subjects: 0
Study 14672103 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of liquids (one trained as causal)
Number of subjects: 0
Study 10746528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lumbar and sacral plexus block (30 mL lidocaine 1.33% with epinephrine for posterior lumbar plexus block, 10 mL same mixture for parasacral block, and 5 mL lidocaine 1% for iliac crest block)
Number of subjects: 29
Study 10746528 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine spinal anesthesia (3 mL 0.5% plain bupivacaine)
Number of subjects: 29
Study 10746528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lumbar and sacral plexus block
Number of subjects: 29
Study 10746528 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine spinal anesthesia
Number of subjects: 29
Study 10746528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lumbar and sacral plexus block and plain bupivacaine spinal anesthesia
Number of subjects: 29
Study 8265272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 12
Study 8265272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 12
Study 8265272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8265272 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 12
Study 3492413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1.0 g qid
Number of subjects: 24
Study 3492413 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 2.5 g
Number of subjects: 24
Study 31977558 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing group
Number of subjects: 40
Study 31977558 — intervention group
Group type: COMPARATOR
Intervention: Conventional method group
Number of subjects: 40
Study 30467685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spironolactone (25 mg/d) plus vitamin E (400 IU/d) for 52 weeks
Number of subjects: 55
Study 30467685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d) for 52 weeks
Number of subjects: 55
Study 30467685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study 27639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naproxen sodium 660 mg once daily
Number of subjects: 0
Study 27639137 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release naproxen sodium 220 mg twice daily (440 mg initially, followed by 220 mg 12 hours later)
Number of subjects: 0
Study 24415649 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antithymocyte globulin (h‐ATG) plus cyclosporine (CsA)
Number of subjects: 25
Study 24415649 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/CsA (initial therapy)
Number of subjects: 25
Study 24415649 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for the cohort
Number of subjects: 25
Study 23134959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with fentanyl (Group DF)
Number of subjects: 80
Study 23134959 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (Group F)
Number of subjects: 80
Study 20837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stereoscopic fundus photographs
Number of subjects: 60
Study 20837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized fluorescein angiograms
Number of subjects: 60
Study 20837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal reproducibility
Number of subjects: 60
Study 20837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporaneous reproducibility
Number of subjects: 60
Study 18363528 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation program (113 patients)
Number of subjects: 521
Study 18363528 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (408 patients)
Number of subjects: 521
Study 15821181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2 g/d)
Number of subjects: 58
Study 15821181 — intervention group
Group type: COMPARATOR
Intervention: Soy oil (2 g/d)
Number of subjects: 58
Study 12898858 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT gene polymorphism (M235T)
Number of subjects: 90
Study 12898858 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1R gene polymorphism (A1166C)
Number of subjects: 90
Study 12898858 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele of A1166C polymorphism
Number of subjects: 90
Study 12898858 — intervention group
Group type: COMPARATOR
Intervention: ACE gene polymorphism (insertion/deletion)
Number of subjects: 90
Study 10716040 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine administered in combination with chlorpheniramine maleate at 2200 hours
Number of subjects: 4
Study 10716040 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine administered in combination with chlorpheniramine maleate at 1000 hours
Number of subjects: 4
Study 8538480 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate (days 1‐21) + 1 mg cyproterone acetate (days 12‐21)
Number of subjects: 60
Study 8538480 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17 beta‐oestradiol (50 micrograms twice weekly during three weeks) + 20 mg dydrogesterone (days 12‐21)
Number of subjects: 60
Study 1779005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin iontophoresis plus dressing changes every 6 hours and cleaning
Number of subjects: 15
Study 1779005 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 15
Study 1779005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin iontophoresis
Number of subjects: 15
Study 7368149 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin (2,500 u pre‐operatively then 5,000 u 12‐hourly for 7 days)
Number of subjects: 24
Study 7368149 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (control group)
Number of subjects: 24
Study 31989330 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed extended-release HPMC niacin formulation
Number of subjects: 0
Study 31989330 — intervention group
Group type: COMPARATOR
Intervention: Originator extended-release niacin product
Number of subjects: 0
Study 30297210 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftazone 160 mg/day
Number of subjects: 16
Study 30297210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28662378 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible lightwand (Group L)
Number of subjects: 60
Study 28662378 — intervention group
Group type: COMPARATOR
Intervention: Conventional ETT withdrawal (Group W)
Number of subjects: 60
Study 26795957 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiannual fluoride varnish applications every 6 months
Number of subjects: 3403
Study 26795957 — intervention group
Group type: COMPARATOR
Intervention: Standardized oral health program once yearly between 1 and 3 years of age (Control)
Number of subjects: 3403
Study 24115314 — intervention group
Group type: COMPARATOR
Intervention: Bolus calculator and wireless communication between insulin pump and blood glucose metre (Group A)
Number of subjects: 156
Study 24115314 — intervention group
Group type: COMPARATOR
Intervention: Bolus calculator without communication (Group B)
Number of subjects: 156
Study 24115314 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (Group C)
Number of subjects: 156
Study 24115314 — intervention group
Group type: COMPARATOR
Intervention: Bolus calculator function (Group A)
Number of subjects: 156
Study 24115314 — intervention group
Group type: COMPARATOR
Intervention: Bolus calculator function (Group B)
Number of subjects: 156
Study 24115314 — intervention group
Group type: COMPARATOR
Intervention: Glycated haemoglobin levels (Group A)
Number of subjects: 156
Study 24115314 — intervention group
Group type: COMPARATOR
Intervention: Post-prandial glycaemia, body mass index-SD score, insulin/kg/24 h (Group A)
Number of subjects: 156
Study 21499896 — intervention group
Group type: EXPERIMENTAL
Intervention: Patupilone combined with midazolam 4 mg PO (days 1 and 29)
Number of subjects: 46
Study 21499896 — intervention group
Group type: EXPERIMENTAL
Intervention: Patupilone combined with omeprazole 40 mg PO (days 1 and 29)
Number of subjects: 46
Study 21499896 — intervention group
Group type: EXPERIMENTAL
Intervention: Patupilone
Number of subjects: 46
Study 19700170 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmic drugs (AADs)
Number of subjects: 500
Study 19700170 — intervention group
Group type: COMPARATOR
Intervention: Not taking class III antiarrhythmic drugs (AADs)
Number of subjects: 500
Study 19700170 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intracardiac QT variability
Number of subjects: 500
Study 19700170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac QT variability index
Number of subjects: 500
Study 17915799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium feredetate (33 mg elemental iron) with vitamin B12 (15 microg) and folic acid (1.5 mg) administered twice a day (Group A)
Number of subjects: 48
Study 17915799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium feredetate (66 mg elemental iron) with vitamin B12 (15 microg) and folic acid (1.5 mg) administered twice a day (Group B)
Number of subjects: 48
Study 17915799 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate (100 mg elemental iron) with vitamin B12 (15 microg) and folic acid (1.5 mg) administered twice a day (Group C)
Number of subjects: 48
Study 15205383 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of [(14)C]capravirine (1400 mg)
Number of subjects: 10
Study 15205383 — intervention group
Group type: COMPARATOR
Intervention: Multiple oral doses of ritonavir (100 mg) followed by a single oral dose of [(14)C]capravirine (1400 mg)
Number of subjects: 10
Study 11284795 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (SIT)
Number of subjects: 0
Study 11284795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11284795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 9222182 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-14117 240 mg per day
Number of subjects: 30
Study 9222182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8165451 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern dentinal adhesive (Prisma Universal Bond 3) without cavity liner
Number of subjects: 60
Study 8165451 — intervention group
Group type: COMPARATOR
Intervention: Light-cured glass-ionomer liner with modern dentinal adhesive
Number of subjects: 60
Study 3662059 — intervention group
Group type: EXPERIMENTAL
Intervention: LE + NaHCO3 (0.1 mEq/ml anesthetic solution)
Number of subjects: 21
Study 3662059 — intervention group
Group type: COMPARATOR
Intervention: LE alone
Number of subjects: 21
Study 29766318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg tablet once daily
Number of subjects: 94
Study 29766318 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 94
Study 27805026 — intervention group
Group type: COMPARATOR
Intervention: AERAS-402 vaccine
Number of subjects: 0
Study 24974961 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprasacral technique
Number of subjects: 20
Study 24974961 — intervention group
Group type: COMPARATOR
Intervention: Lumbar plexus block
Number of subjects: 20
Study 22776761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-CP
Number of subjects: 67
Study 22776761 — intervention group
Group type: COMPARATOR
Intervention: In-Person CP
Number of subjects: 67
Study 20686011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tables
Number of subjects: 408
Study 20686011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictographs
Number of subjects: 408
Study 20686011 — intervention group
Group type: COMPARATOR
Intervention: Standard text
Number of subjects: 408
Study 18392313 — intervention group
Group type: EXPERIMENTAL
Intervention: Steamed buns (bao)
Number of subjects: 0
Study 18392313 — intervention group
Group type: COMPARATOR
Intervention: Control food
Number of subjects: 0
Study 16192545 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE using bupivacaine 0.5% for spinal anesthesia and ropivacaine 0.2% with 0.5 microg/mL of sufentanil for postoperative epidural analgesia (CSE; n = 8)
Number of subjects: 16
Study 16192545 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia followed by IV patient‐controlled analgesia with piritramide (control; n = 8)
Number of subjects: 16
Study 12578921 — intervention group
Group type: EXPERIMENTAL
Intervention: Spike-triggered fMRI during silent reading
Number of subjects: 2
Study 12578921 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of left central sulcal patterns in subjects with RE
Number of subjects: 2
Study 12578921 — intervention group
Group type: EXPERIMENTAL
Intervention: Spike activity during reading
Number of subjects: 2
Study 10480779 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT) group
Number of subjects: 77
Study 10480779 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire group
Number of subjects: 77
Study 10480779 — intervention group
Group type: COMPARATOR
Intervention: Normal Glucose Tolerance (NGT) group
Number of subjects: 77
Study 8608877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (Pentasa) 4 g . day(‐1)
Number of subjects: 150
Study 8608877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 1765056 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% VO2max
Number of subjects: 12
Study 1765056 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% VO2max
Number of subjects: 12
Study 6604081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben (100 mg orally three times once every 4 hr)
Number of subjects: 17
Study 6604081 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study 31775405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 72
Study 31775405 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 72
Study 29049415 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 72
Study 29049415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27574399 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin)
Number of subjects: 162
Study 27574399 — intervention group
Group type: COMPARATOR
Intervention: olmesartan medoxomil (40 mg)
Number of subjects: 162
Study 27574399 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin (20 mg)
Number of subjects: 162
Study 25048851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (2 g/6 hours IV) plus Imipenem (1 g/6 hours IV)
Number of subjects: 16
Study 22867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Hypertension (PH)
Number of subjects: 75
Study 22867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin level
Number of subjects: 75
Study 22867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 75
Study 22867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular water
Number of subjects: 75
Study 22867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrium enlargement
Number of subjects: 75
Study 19573818 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy (LPS)
Number of subjects: 80
Study 19573818 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomic myomectomy (MLPT)
Number of subjects: 80
Study 17610432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not provided)
Number of subjects: 479
Study 17610432 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific control details not provided)
Number of subjects: 479
Study 15355139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-OSPAN individuals
Number of subjects: 0
Study 15355139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-OSPAN individuals
Number of subjects: 0
Study 11354529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg per week)
Number of subjects: 16
Study 10052233 — intervention group
Group type: EXPERIMENTAL
Intervention: Valgus high tibial osteotomy
Number of subjects: 21
Study 10052233 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with the limb extrarotated
Number of subjects: 21
Study 8028614 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (20 mg twice daily for four weeks)
Number of subjects: 163
Study 8028614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for four weeks)
Number of subjects: 163
Study 2733080 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of a 10% glucose polymer solution at 20 min intervals during exercise (CHO)
Number of subjects: 9
Study 2733080 — intervention group
Group type: COMPARATOR
Intervention: Sweet placebo (CON)
Number of subjects: 9
Study 1221326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug therapy (5 FU, methotrexate, vincristine, cyclophosphamide, and prednisone)
Number of subjects: 100
Study 1221326 — intervention group
Group type: COMPARATOR
Intervention: 4-drug therapy (5 FU, methotrexate, vincristine, cyclophosphamide)
Number of subjects: 100
Study 1221326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug therapy
Number of subjects: 100
Study 1221326 — intervention group
Group type: COMPARATOR
Intervention: 4-drug therapy
Number of subjects: 100
Study 29443537 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion-preserved hamstring tendon graft
Number of subjects: 45
Study 29443537 — intervention group
Group type: COMPARATOR
Intervention: Insertion-detached hamstring tendon graft
Number of subjects: 45
Study 27931556 — intervention group
Group type: EXPERIMENTAL
Intervention: NPHW intervention
Number of subjects: 100
Study 27931556 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 24644541 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly vitamin D supplementation (cholecalciferol; 50,000 units for 12 weeks)
Number of subjects: 60
Study 24644541 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60